Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972335 · ClinicalTrials.gov registry record · Phase 2
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00972335 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 18 participants.
The verdict
NCT00972335, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relatively rare, there is currently no established standard of treatment for a disease that causes a great deal of morbidity, and that is eventually fatal.
Interventions
- DRUG Bevacizumab
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972335
The ClinicalTrials.gov registry entry for NCT00972335 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00972335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00972335 about?
NCT00972335 is a clinical study titled "Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma". In this multicenter, Phase II trial, the investigators plan to evaluate the activity of the combination of bevacizumab and everolimus in patients with recurrent, progressive meningioma following maximal treatment with surgical resection and local radiation therapy. Although these patients are relati...
What is the current status of trial NCT00972335?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2010-01. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00972335?
The interventions under investigation include: Bevacizumab (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT00972335?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.